NCT01981161View on ClinicalTrials.gov

Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis

CompletedOBSERVATIONAL

Enrollment

307

Participants

Timeline

Start Date

November 19, 2013

Primary Completion Date

June 20, 2018

Study Completion Date

November 30, 2018

Conditions

Multiple Sclerosis

Interventions

PROCEDURE

biological samples and clinical data

Trial Locations (12)

13385

Chu La Timone, Marseille

14033

CHU Caen, Caen

25000

CHU Besançon, Besançon

30029

CHU Nîmes, Nîmes

44093

CHU Nantes, Nantes

54035

CHU Nancy, Nancy

59037

Chu Lille, Lille

67098

CHRU Strasbourg, Strasbourg

33 000

CHU Bordeaux, Bordeaux

06002

CHU Nice, Nice

Unknown

Université de Muenter, Münster

Hôpital Vall D'Hebron, Barcelona

All Listed Sponsors

collaborator

European Commission

OTHER

lead

University Hospital, Toulouse

OTHER

NCT01981161 - Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis | Biotech Hunter | Biotech Hunter